https://www.selleckchem.com/pr....oducts/itacitinib-in
Several app-related parameters were evaluated. Patient-related outcome measures were investigated in the test group. RESULTS Test and control groups were similar at baseline except for WSL score. Between T1 and T4, PI and GI decreased significantly in both groups but evolutions were globally similar in both groups. Interestingly, at T3 (12 weeks), the PI was significantly lower in the app group than in the control group (P = 0.014). Data showed a marked decline in the use of the app over time in the test group. CONCLUSIONS
Like
Comment
Share
